Cardiovascular safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients: A prospective evaluation

Veronica Prati, Fiorella Ruatta, Caterina Aversa, Angela Gernone, Danilo Galizia, Alessandro Bonzano, Sofia Torino, Imperia Nuzzolese, Laura Marandino, Massimo Aglietta, Cinzia Ortega

Research output: Contribution to journalArticlepeer-review

Abstract

Aim: The aim of this study is to evaluate cardiotoxicity of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer patients (pts) with cardiovascular comorbidities or coronary artery disease (CAD) risk factors. Patients & methods: We prospectively analyzed pts receiving AA in order to evaluate correlations between cardiotoxicity onset and CAD risk factors or cardiovascular comorbidities. Results: Eighty-seven pts were enrolled, with median treatment duration of 9 months (1-44). At baseline, 84 pts (96%) had CAD risk factors. During treatment four pts (4; 6%) developed hypertension and 26 pts (30%) worsened the preexisting hypertension. Median left ventricular ejection fraction were 64 and 63% at baseline and after treatment, respectively. Conclusion: AA appears to be safe in pts with cardiovascular comorbidities or CAD risk factors.

Original languageEnglish
Pages (from-to)443-448
Number of pages6
JournalFuture Oncology
Volume14
Issue number5
DOIs
Publication statusPublished - Feb 1 2018

Keywords

  • abiraterone acetate
  • cardiovascular risk factors
  • frail patients
  • metastatic castration-resistant prostate cancer
  • multidisciplinary management
  • prospective study
  • safety

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Cardiovascular safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients: A prospective evaluation'. Together they form a unique fingerprint.

Cite this